Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017

Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the fourth quarter...

Aptevo To Present New Data at Cancer Meeting

Aptevo Therapeutics announced the presentation of new clinical data for APVO436 and APVO437 at the upcoming American Association for Cancer...